Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 123Thoracic 55Genitourinary 49Gastrointestinal 44Head & Neck 17Tumor-Agnostic 15Sarcoma 15Other solid neoplasm 15CNS 15Gynecologic 14Lymphoid 12Breast 11Other hematologic neoplasm 8Myeloid 6Plasma cell 4Endocrine 3NET 1

Conditions

Neuroendocrine Tumors 1Gastrointestinal Neoplasms 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ipilimumab × NET × Clear all
NCT02923934 2024-07-24

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Olivia Newton-John Cancer Research Institute

Phase 2 Completed
120 enrolled
EndocrineGastrointestinalNET

Gastrointestinal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡